Background: High doses of the histone deacetylase inhibitor Valproic Acid (VPA, 150-400 mg/kg) improve outcomes in animal models of lethal insults. We are conducting an FDA approved phase 1, double blind, placebo-controlled trial to evaluate the safety and tolerability of ascending doses of VPA in human volunteers. We hypothesized that VPA would induce significant changes in the proteome of healthy humans when given at doses lower than those used in prior animal studies.
|Effective start/end date||9/1/20 → 9/29/22|
- U.S. Army Medical Research and Materiel Command (W81XWH-17-1-0701)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.